{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:02:56Z","timestamp":1778090576886,"version":"3.51.4"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Lupus nephritis is typically treated with intravenous cyclophosphamide, which is associated with serious adverse effects. Oral mizoribine may be an alternative for induction therapy of lupus nephritis. However, large-scale, long-term, randomized clinical studies of mizoribine are lacking.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the efficacy and safety of oral mizoribine vs intravenous cyclophosphamide as induction therapy for Chinese patients with lupus nephritis.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prospective, multicenter, parallel-group, open-label, phase 3 randomized clinical trial recruited patients with class III, III+V, IV, IV+V, or V lupus nephritis aged 18 to 70 years from 40 centers in China. Inclusion criteria included 24-hour urinary protein level of 1.0 g or higher and systemic lupus erythematosus disease activity index of 8 or higher. The first patient was enrolled on November 29, 2014, and the study finished March 14, 2019. The follow-up period was 52 weeks. Data were analyzed from September 4, 2019, to January 21, 2020.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Oral mizoribine (50 mg, 3 times a day) or cyclophosphamide (6 intravenous doses at 0.5-1.0 g\/m2<\/jats:sup> body surface area, with a maximum dose of 1.0 g\/d) for 52 weeks plus oral glucocorticoid.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Total remission rate (complete remission rate plus partial remission rate) after 52 weeks (prespecified).<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 250 patients were randomized, and 243 patients (mean [SD] age, 34.6 [10.7] years, 213 women [87.7%]) were treated (123 patients [50.6%] in the mizoribine group and 120 patients [49.4%] in the cyclophosphamide group). The total remission rate at 52 weeks was 66.1% (76 of 115 patients) in the mizoribine group and 76.8% (86 of 112 patients) in the cyclophosphamide group, and the relative risk ratio (mizoribine vs cyclophosphamide) was 0.861 (95% CI, 0.729-1.016). The lower limit of this 2-sided 95% CI was greater than the noninferiority margin of 0.726, indicating that mizoribine was noninferior to cyclophosphamide. Changes in other immune parameters and kidney function were generally similar between the groups. The incidence of any treatment-related treatment-emergent adverse events was 80.5% (99 of 123 patients) in the mizoribine group and 78.7% (96 of 122 patients) in the cyclophosphamide group, and the most frequent adverse event in both groups was upper respiratory tract infection (41 patients [33.3%] and 37 patients [30.3%], respectively).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This randomized clinical trial shows that compared with intravenous cyclophosphamide, oral mizoribine was noninferior and well tolerated when used with glucocorticoid for induction therapy of active lupus nephritis. Mizoribine can be used as an alternative to intravenous cyclophosphamide as induction therapy for lupus nephritis.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02256150<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.0648","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:31:43Z","timestamp":1741966303000},"page":"e250648","source":"Crossref","is-referenced-by-count":7,"title":["Mizoribine or Cyclophosphamide for Lupus Nephritis"],"prefix":"10.1001","volume":"8","author":[{"given":"Zheyi","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People\u2019s Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiren","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of Air Force Medical University of PLA, Xi\u2019an, Shaanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohui","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yani","family":"He","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Army Medical Center of PLA, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Liuzhou Worker\u2019s Hospital, Liuzhou, Guanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangsuo","family":"Liu","sequence":"additional","affiliation":[{"name":"Research Institute of Nephrology, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenbiao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Xijing Hospital, Air Force Medical University (Fourth Military Medical University), Xi\u2019an, Shaanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinzhou","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shenzhen People\u2019s Hospital, Shenzhen, Guandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhua","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Immunology, Jining First People\u2019s Hospital, Jining, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongli","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatism and Immunology, Guangdong Provincial People\u2019s Hospital, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongguo","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohua","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shanxi Medical University Second Hospital, Taiyuan, Shanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuefei","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aerospace Center Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The 960th Hospital of PLA Joint Logistics Support Force, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatism and Immunology, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The 920th Hospital of PLA Joint Logistics Support Force, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shandong Provincial Hospital, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenge","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxin","family":"Wan","sequence":"additional","affiliation":[{"name":"Blood Purification Research Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianjun","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Immunology, Peking University Third Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongguang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Nephrology, General Hospital of Northern Theater Command, Shenyang, Liaoning, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianghua","family":"Chen","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Shangcheng, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Rheumatism, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seika","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Asahi Kasei Pharma Corporation, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[{"name":"Asahi Kasei Pharma (Beijing) Co, Ltd, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-yan","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People\u2019s Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People\u2019s Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangmei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People\u2019s Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"issue":"9","key":"zoi250054r1","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2-#","article-title":"Guidelines for referral and management of systemic lupus erythematosus in adults.","volume":"42","author":"American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"9561","key":"zoi250054r2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(07)60279-7","article-title":"Systemic lupus erythematosus.","volume":"369","author":"D\u2019Cruz","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"zoi250054r3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies.","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"zoi250054r4","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1177\/0961203310374305","article-title":"Epidemiology of systemic lupus erythematosus in Asia.","volume":"19","author":"Osio-Salido","year":"2010","journal-title":"Lupus"},{"issue":"2","key":"zoi250054r5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study.","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"zoi250054r6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.05780616","article-title":"Update on lupus nephritis.","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"zoi250054r7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MAJ.0b013e31827f4ee3","article-title":"Lupus nephritis and end-stage kidney disease.","volume":"346","author":"Maroz","year":"2013","journal-title":"Am J Med Sci"},{"issue":"6","key":"zoi250054r8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"zoi250054r9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis.","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"zoi250054r10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/ncpneph0915","article-title":"Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price?","volume":"4","author":"Philibert","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"issue":"23","key":"zoi250054r11","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1016\/0006-2952(83)90301-5","article-title":"Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells.","volume":"32","author":"Koyama","year":"1983","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"zoi250054r12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cbf.290070308","article-title":"Dual inhibitory effect of bredinin.","volume":"7","author":"Kusumi","year":"1989","journal-title":"Cell Biochem Funct"},{"issue":"7","key":"zoi250054r13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2174\/092986730607220401123549","article-title":"Mizoribine and mycophenolate mofetil.","volume":"6","author":"Ishikawa","year":"1999","journal-title":"Curr Med Chem"},{"issue":"1","key":"zoi250054r14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/14397595.2017.1349573","article-title":"Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-year results.","volume":"28","author":"Takeuchi","year":"2018","journal-title":"Mod Rheumatol"},{"key":"zoi250054r15","doi-asserted-by":"crossref","DOI":"10.1177\/2050312114533960","article-title":"Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis: safety and efficacy during a 3-year follow-up.","volume":"2","author":"Yagi","year":"2014","journal-title":"SAGE Open Med"},{"key":"zoi250054r16","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.130266.1","article-title":"Efficacy and safety of mizoribine in comparison with cyclophosphamide for treatment of lupus nephritis: protocol for a multi-center, open-label, randomized controlled trial.","author":"Dong","year":"2023","journal-title":"F1000Research"},{"issue":"20","key":"zoi250054r17","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"9","key":"zoi250054r18","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"6","key":"zoi250054r19","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. a disease activity index for lupus patients.","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"2","key":"zoi250054r20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited.","volume":"15","author":"Weening","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"zoi250054r21","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"11","key":"zoi250054r22","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1007\/s00296-013-2804-2","article-title":"Study of the efficacy of mizoribine in lupus nephritis in Chinese patients.","volume":"33","author":"Zhang","year":"2013","journal-title":"Rheumatol Int"},{"issue":"7","key":"zoi250054r23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/0961203308089408","article-title":"Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.","volume":"17","author":"Wang","year":"2008","journal-title":"Lupus"},{"issue":"5","key":"zoi250054r24","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort.","volume":"67","author":"Dall\u2019Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"zoi250054r25","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis.","volume":"75","author":"Tamirou","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"zoi250054r26","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s10157-018-1597-8","article-title":"The first year results of mizoribine\/tacrolimus-based multitarget treatment for consecutive patients with lupus nephritis.","volume":"22","author":"Kagawa","year":"2018","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"zoi250054r27","doi-asserted-by":"crossref","first-page":"355.e25","DOI":"10.1016\/j.amjmed.2005.08.045","article-title":"Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.","volume":"119","author":"Mok","year":"2006","journal-title":"Am J Med"},{"issue":"5","key":"zoi250054r28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"zoi250054r29","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus.","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"17","key":"zoi250054r30","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000794","article-title":"Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies.","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Baltimore)"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2831510\/dong_2025_oi_250054_1741359380.51634.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:31:54Z","timestamp":1741966314000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2831510"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.0648","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]}}}